Fecal immunochemical test as a biomarker for inflammatory bowel diseases

Can it rival fecal calprotectin?

Jun Kato, Sakiko Hiraoka, Asuka Nakarai, Shiho Takashima, Toshihiro Inokuchi, Masao Ichinose

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity, but the procedures are sometimes invasive and burdensome to patients. Therefore, alternative non-invasive methods for evaluating or predicting disease activity including mucosal status are desirable. Fecal calprotectin (Fcal) is the most widely used fecal marker for IBD, and many articles have described the performance of the marker in predicting disease activity, mucosal healing (MH), treatment efficacy, and risk of relapse. Fecal immunochemical test (FIT) can quantify the concentration of hemoglobin in stool and was originally used for the screening of colorectal cancer. We recently reported that FIT is also a useful biomarker for IBD. A direct comparison between the use of Fcal and FIT showed that both methods predicted MH in ulcerative colitis equally well. However, in the case of Crohn's disease, FIT was less sensitive to lesions in the small intestine, compared to Fcal. FIT holds several advantages over Fcal in regards to user-friendliness, including a lower cost, easy and clean handling, and the ability to make rapid measurements by using an automated measurement system. However, there is insufficient data to support the application of FIT in IBD. Further studies into the use of FIT for evaluating the inflammatory status of IBD are warranted.

Original languageEnglish
Pages (from-to)5-14
Number of pages10
JournalIntestinal Research
Volume14
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Leukocyte L1 Antigen Complex
Inflammatory Bowel Diseases
Biomarkers
Ulcerative Colitis
Crohn Disease
Endoscopy
Small Intestine
Colorectal Neoplasms
Hemoglobins
Costs and Cost Analysis
Recurrence

Keywords

  • Crohn disease
  • Endoscopy
  • Fecal calprotectin
  • Fecal immunochemical test
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fecal immunochemical test as a biomarker for inflammatory bowel diseases : Can it rival fecal calprotectin? / Kato, Jun; Hiraoka, Sakiko; Nakarai, Asuka; Takashima, Shiho; Inokuchi, Toshihiro; Ichinose, Masao.

In: Intestinal Research, Vol. 14, No. 1, 2016, p. 5-14.

Research output: Contribution to journalReview article

Kato, Jun ; Hiraoka, Sakiko ; Nakarai, Asuka ; Takashima, Shiho ; Inokuchi, Toshihiro ; Ichinose, Masao. / Fecal immunochemical test as a biomarker for inflammatory bowel diseases : Can it rival fecal calprotectin?. In: Intestinal Research. 2016 ; Vol. 14, No. 1. pp. 5-14.
@article{0e1b56cbb42f4cc1a6f456275306d1dd,
title = "Fecal immunochemical test as a biomarker for inflammatory bowel diseases: Can it rival fecal calprotectin?",
abstract = "Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity, but the procedures are sometimes invasive and burdensome to patients. Therefore, alternative non-invasive methods for evaluating or predicting disease activity including mucosal status are desirable. Fecal calprotectin (Fcal) is the most widely used fecal marker for IBD, and many articles have described the performance of the marker in predicting disease activity, mucosal healing (MH), treatment efficacy, and risk of relapse. Fecal immunochemical test (FIT) can quantify the concentration of hemoglobin in stool and was originally used for the screening of colorectal cancer. We recently reported that FIT is also a useful biomarker for IBD. A direct comparison between the use of Fcal and FIT showed that both methods predicted MH in ulcerative colitis equally well. However, in the case of Crohn's disease, FIT was less sensitive to lesions in the small intestine, compared to Fcal. FIT holds several advantages over Fcal in regards to user-friendliness, including a lower cost, easy and clean handling, and the ability to make rapid measurements by using an automated measurement system. However, there is insufficient data to support the application of FIT in IBD. Further studies into the use of FIT for evaluating the inflammatory status of IBD are warranted.",
keywords = "Crohn disease, Endoscopy, Fecal calprotectin, Fecal immunochemical test, Ulcerative colitis",
author = "Jun Kato and Sakiko Hiraoka and Asuka Nakarai and Shiho Takashima and Toshihiro Inokuchi and Masao Ichinose",
year = "2016",
doi = "10.5217/ir.2016.14.1.5",
language = "English",
volume = "14",
pages = "5--14",
journal = "Intestinal Research",
issn = "1598-9100",
publisher = "Korean Association for the Study of Intestinal Diseases",
number = "1",

}

TY - JOUR

T1 - Fecal immunochemical test as a biomarker for inflammatory bowel diseases

T2 - Can it rival fecal calprotectin?

AU - Kato, Jun

AU - Hiraoka, Sakiko

AU - Nakarai, Asuka

AU - Takashima, Shiho

AU - Inokuchi, Toshihiro

AU - Ichinose, Masao

PY - 2016

Y1 - 2016

N2 - Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity, but the procedures are sometimes invasive and burdensome to patients. Therefore, alternative non-invasive methods for evaluating or predicting disease activity including mucosal status are desirable. Fecal calprotectin (Fcal) is the most widely used fecal marker for IBD, and many articles have described the performance of the marker in predicting disease activity, mucosal healing (MH), treatment efficacy, and risk of relapse. Fecal immunochemical test (FIT) can quantify the concentration of hemoglobin in stool and was originally used for the screening of colorectal cancer. We recently reported that FIT is also a useful biomarker for IBD. A direct comparison between the use of Fcal and FIT showed that both methods predicted MH in ulcerative colitis equally well. However, in the case of Crohn's disease, FIT was less sensitive to lesions in the small intestine, compared to Fcal. FIT holds several advantages over Fcal in regards to user-friendliness, including a lower cost, easy and clean handling, and the ability to make rapid measurements by using an automated measurement system. However, there is insufficient data to support the application of FIT in IBD. Further studies into the use of FIT for evaluating the inflammatory status of IBD are warranted.

AB - Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity, but the procedures are sometimes invasive and burdensome to patients. Therefore, alternative non-invasive methods for evaluating or predicting disease activity including mucosal status are desirable. Fecal calprotectin (Fcal) is the most widely used fecal marker for IBD, and many articles have described the performance of the marker in predicting disease activity, mucosal healing (MH), treatment efficacy, and risk of relapse. Fecal immunochemical test (FIT) can quantify the concentration of hemoglobin in stool and was originally used for the screening of colorectal cancer. We recently reported that FIT is also a useful biomarker for IBD. A direct comparison between the use of Fcal and FIT showed that both methods predicted MH in ulcerative colitis equally well. However, in the case of Crohn's disease, FIT was less sensitive to lesions in the small intestine, compared to Fcal. FIT holds several advantages over Fcal in regards to user-friendliness, including a lower cost, easy and clean handling, and the ability to make rapid measurements by using an automated measurement system. However, there is insufficient data to support the application of FIT in IBD. Further studies into the use of FIT for evaluating the inflammatory status of IBD are warranted.

KW - Crohn disease

KW - Endoscopy

KW - Fecal calprotectin

KW - Fecal immunochemical test

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85006036399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006036399&partnerID=8YFLogxK

U2 - 10.5217/ir.2016.14.1.5

DO - 10.5217/ir.2016.14.1.5

M3 - Review article

VL - 14

SP - 5

EP - 14

JO - Intestinal Research

JF - Intestinal Research

SN - 1598-9100

IS - 1

ER -